ALLK - Allakos Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

188.9M

Cash

252.6M

Avg Qtr Burn

-33.96M

Short % of Float

6.55%

Insider Ownership

4.42%

Institutional Own.

85.84%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lirentelimab (AK002) (Siglec-8) Details Chronic urticaria Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lirentelimab (AK002) Details Atopic dermatitis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Esophagitis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Duodentitis , Eosinophilic Gastritis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.